Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093951
Status:
COMPLETED
Last Update Posted:
2009-12-11
First Post:
2004-10-07
Brief Title:
SGS742 in Patients With Mild to Moderate Alzheimers Disease AD
Sponsor:
Saegis Pharmaceuticals
Organization:
National Institute on Aging NIA
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the effect of a new drug SGS742 on memory and cognition in patients with mild to moderate Alzheimers disease
Detailed Description:
SGS742 is a GABAB receptor antagonist It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimers disease The duration of the study is 3 months with 5 clinic visits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None